Related Experiment Video
Updated: Nov 26, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Gender differences in treatment of Coronavirus Disease-2019
Immacolata Ambrosino1, Elena Barbagelata2, Graziamaria Corbi3
1Local Healthcare Unit of Bari, Health District 10. imma-ambrosino@libero.it.
Insights
COVID-19 disproportionately affects men, especially those with underlying conditions. Analyzing treatment data by sex is crucial for developing effective, personalized therapies to reduce severe illness and mortality.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Coronavirus Disease-2019 (COVID-19) became a global pandemic with significant mortality.
- Men exhibited higher infection rates and severe outcomes, particularly with comorbidities like diabetes and hypertension.
- Biological factors, including hormonal influences and X-linked gene activity, may explain gender-based disparities in immune response to viral infections.
Purpose of the Study:
- To review existing studies on COVID-19 treatments, assessing available data for gender-specific analysis.
- To highlight the importance of sex-disaggregated data in understanding COVID-19 outcomes and treatment efficacy.
- To emphasize the need for customized treatment strategies based on gender, age, and race.
Main Methods:
- Systematic review of published studies on various COVID-19 drugs: chloroquine/hydroxychloroquine, remdesivir, favipiravir, lopinavir-ritonavir, tocilizumab, plasma, and immunoglobulins.
- Evaluation of gender analysis within the selected studies.
- Analysis of factors contributing to gender disparities in disease severity and mortality.
Main Results:
- Limited studies reported gender-specific data for COVID-19 treatments.
- Observed disparities in infection rates and disease severity between men and women.
- Underlying health conditions in men correlated with increased risk of severe COVID-19 and higher mortality.
Conclusions:
- Sex-disaggregated data reporting is essential for understanding COVID-19.
- Knowledge of gender differences is fundamental for developing effective, personalized treatments.
- Tailoring treatments based on sex, age, and race can reduce hospitalizations, ICU admissions, and mortality.
Abstract:
Coronavirus Disease-2019 (COVID-19) is the worst worldwide pandemic with more than 12,000,000 cases and 560,000 deaths until 14th July 2020. Men were more infected by COVID-19 than women, and male subjects with underlying conditions, including diabetes, hypertension, and cardiovascular diseases developed a severe form of the affection, with increased mortality rate. Many factors can contribute to the disparity in disease outcomes, such as hormone-specific reaction and activity of X-linked genes, which modulate the innate and adaptive immune response to virus infection. Until now, only the Remdesivir was approved by FDA (Food Drug Administration) for COVID-19 treatment, although several clinical trials are ongoing worldwide also on other drugs. In this review, we analyzed published studies on several drugs (chloroquine or hydroxychloroquine, remdesivir, favipiravir, lopinavir-ritonavir in combination, tocilizumab, plasma, and immunoglobulins) with some efficacy to COVID-19 in humans, and evaluated if there were a gender analysis of the available data. In our opinion, it is essential to report data about COVID-19 disaggregated by sex, age, and race, because the knowledge of gender differences is fundamental to identify effective and customized treatments to reduce hospitalizations, admissions to intensive care units, and mortality.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Related Concept Videos
Panic Disorder
Socioemotional Experience and Gender Development
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation